Amotiv Limited Total Liabilities
Amotiv Limited total liabilities. Based on the latest financial reports, Amotiv Limited (AOV) has total liabilities worth CA$279.03 Million CAD (≈ $201.84 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AOV financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Amotiv Limited (2014–2025)
Total liabilities of Amotiv Limited from 2014 to 2025. This chart illustrates how Amotiv Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Amotiv Limited long-term investment intensity to see how much of total assets are deployed in long-term investments.
Amotiv Limited Competitors by Total Liabilities
The table below lists competitors of Amotiv Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Limbach Holdings Inc
NASDAQ:LMB
|
USA | $200.86 Million |
|
LG Balakrishnan & Bros Limited
NSE:LGBBROSLTD
|
India | Rs7.58 Billion |
|
First Hi-tec Enterprise Co Ltd
TWO:5439
|
Taiwan | NT$6.87 Billion |
|
Flytech Technology Co Ltd
TW:6206
|
Taiwan | NT$1.32 Billion |
|
Autohellas S.A.
AT:OTOEL
|
Greece | €1.20 Billion |
|
Great Lakes Dredge & Dock
NASDAQ:GLDD
|
USA | $765.63 Million |
|
Voltalia SA
PA:VLTSA
|
France | €3.13 Billion |
|
COFCO Engineering & Technology Co Ltd
SHE:301058
|
China | CN¥2.26 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Amotiv Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Amotiv Limited (AOV) total assets.
Liquidity & Leverage Metrics
Amotiv Limited Total Liabilities Ratios Explained
Amotiv Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.03 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amotiv Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amotiv Limited (2014–2025)
The table below shows the annual total liabilities of Amotiv Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$279.03 Million ≈ $201.84 Million |
+65.41% |
| 2024-12-31 | CA$168.69 Million ≈ $122.03 Million |
-15.07% |
| 2023-12-31 | CA$198.62 Million ≈ $143.68 Million |
-13.26% |
| 2022-12-31 | CA$228.98 Million ≈ $165.64 Million |
+52.78% |
| 2021-12-31 | CA$149.87 Million ≈ $108.42 Million |
-2.32% |
| 2020-12-31 | CA$153.44 Million ≈ $110.99 Million |
-60.68% |
| 2019-12-31 | CA$390.20 Million ≈ $282.26 Million |
+1689.89% |
| 2018-12-31 | CA$21.80 Million ≈ $15.77 Million |
+47.55% |
| 2017-12-31 | CA$14.78 Million ≈ $10.69 Million |
+33.69% |
| 2016-12-31 | CA$11.05 Million ≈ $7.99 Million |
+59.57% |
| 2015-12-31 | CA$6.93 Million ≈ $5.01 Million |
-9.14% |
| 2014-12-31 | CA$7.62 Million ≈ $5.51 Million |
-- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more